CONTRAD SWISS is a Swiss-based pharmaceutical corporation dedicated to revolutionizing regenerative medicine. The company's proprietary SIGMOLECS® Technology represents a significant advancement in the use of peptides as active ingredients. Its portfolio includes medical devices and aesthetic products, positioned in the premium segment, offering exceptional value. The technology guides cell behavior for a wide range of treatments, enhancing the penetration of important molecules and utilizing customized peptide sequences. This breakthrough has led to the creation of specialized non-invasive product lines such as 500Line for osteoarthritis and connective tissue pathology, ACTV8 PRO for regenerative aesthetic physicians, and Egyfil for muscle & joint relief. The company is at the forefront of regenerative medicine, aiming to address unmet clinical needs and signaling the future of the industry. Founded in 2011, CONTRAD SWISS operates in the Biotechnology, Manufacturing, Medical Devices, and Pharmaceutical industries.
There is no investment information
No recent news or press coverage available for CONTRAD SWISS.